Postmortem Donor Regeneration via Stem Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The current organ transplantation field faces a severe organ shortage due to the limited number of viable donors, necessitating innovative methods to enhance organ quality and viability, particularly through in vivo regeneration techniques.
Innovation Solution
The method involves administering regenerative cell populations, such as mesenchymal stem cells or pluripotent stem cells, to a brain-dead patient on life support, stimulating tissue and blood vessel regeneration, and using specific cell markers and treatments to optimize cell function and expansion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If regenerative cell populations are administered to brain-dead patients, then organ quality and viability are improved, but the complexity of the transplantation process increases
Solution Approach 1:
The patent applies preliminary action by administering regenerative cells to brain-dead donors before organ harvesting. This allows the cells to begin regenerative processes and improve organ quality in advance, transforming marginal donors into viable sources. The regenerative cells are introduced early in the donation process to maximize their therapeutic effect on organ viability before transplantation.
Solution Approach 2:
The regenerative cell populations serve as intermediaries between the brain-dead donor and the eventual organ recipient. These cells mediate the transformation of marginal organs into viable grafts by secreting trophic factors, reducing inflammation, and promoting tissue repair. The cells act as a biological bridge that enhances organ quality without requiring direct interaction between donor and recipient.
2Reliability
If the number of marginal donors is reduced, then organ quality is improved, but the available donor pool is decreased
Solution Approach 1:
The patent changes the quality parameters of marginal organs through regenerative cell therapy. By introducing stem cells and progenitor cells that secrete trophic factors and anti-inflammatory cytokines, the organ's viability, structural integrity, and functional capacity are improved. This transforms organs that would previously be considered marginal into viable transplantation candidates, effectively changing their quality classification.
Solution Approach 2:
The patent converts the harm of organ marginality into benefit by using regenerative cells to repair and rejuvenate damaged tissues. Marginal organs, which would normally be discarded due to poor quality, are rescued through cell-mediated regeneration. The previously harmful condition of organ damage is transformed into an opportunity for regenerative enhancement, expanding the usable donor pool.
3Quantity of substance
If regenerative processes are used to rejuvenate organs, then donor pool is expanded, but the time required for organ preparation increases
Solution Approach 1:
The patent implements continuous useful action by initiating regenerative processes immediately upon donor declaration and maintaining them throughout the organ preservation and transplantation process. The regenerative cells continuously secrete trophic factors and anti-inflammatory mediators during organ perfusion, storage, and transport, ensuring ongoing tissue protection and repair without interrupting the transplantation workflow.
Data Source
AI summary
Described are means, methods and compositions of matter useful for enhancing quality of organ transplants by induction of postmortem regeneration. The disclosure provides administration of regenerative cells and/or factors in a brain dead recipient whose body is maintained in a viable state by life supporting machinery.